Why MFM and Behavioral Health Denials Don’t Look Like Everyone Else’s

Generic denial dashboards usually answer a useful but incomplete question: What percentage of claims did not pay as expected? They are much less effective at answering the executive question: What operating condition caused those dollars to fail, and what would prevent the next one?

That gap is especially expensive in MFM and behavioral health. Both specialties sit at the intersection of clinical complexity and administrative specificity. The claim may be technically clean and still fail because the authorization does not match the service performed, the rendering provider is not recognized under the payer’s enrollment configuration, the diagnosis does not support the payer’s medical-necessity logic, or the service falls on the wrong side of a specialty billing boundary.

The same remittance label can therefore represent a front-desk problem, a clinical-documentation problem, a payer-policy problem, a credentialing problem, or a contract problem. Treating all five as “denials” sends the team toward rework instead of prevention.

Maternal-fetal medicine is not simply obstetrics with higher-acuity patients. Its billing architecture combines high-risk evaluation and management, consultation and co-management, ultrasound and other diagnostic services, genetic counseling, diabetes management, remote monitoring, and transfers of care. The Society for Maternal-Fetal Medicine’s current coding education reflects exactly that breadth.²

That creates denial patterns that general benchmarks can miss.

Global-package boundaries create payment logic that other specialties do not have

During 2026, maternity services are still being delivered across a global-obstetric framework in many payer arrangements. The revenue-cycle question is not merely whether an E/M code is valid. It is whether the service is included in maternity care, separately reportable because of a complication or distinct service, billed by the clinician who owns that component of care, or subject to a payer-specific way of processing antepartum services.

When an MFM specialist co-manages a pregnancy rather than assuming full obstetric care, the operational distinction between consultation, co-management, transfer of care, imaging, and additional problem-oriented management becomes financially consequential. A generic “bundled/global” denial bucket does not tell leadership whether the root cause is coding, payer configuration, referral structure, or an incorrect assumption about who owns the maternity package.

Imaging and diagnostic services have their own medical-necessity chain

MFM relies heavily on ultrasound and other diagnostic testing. The denial risk is therefore tied not only to the procedure code, but to the clinical indication, timing, frequency, diagnosis linkage, authorization requirements, and—where applicable—the exact service that was approved versus the service ultimately performed. A scheduling change that is clinically appropriate can still create an authorization mismatch downstream.

Pregnancy diagnosis specificity is operational, not cosmetic

High-risk pregnancy claims often depend on accurate linkage among the maternal condition, gestational age, trimester, and—in multifetal pregnancies—fetal specificity. The more complex the clinical story, the easier it is for documentation, coding, authorization, and claim submission to become misaligned. The result is a denial that looks like “medical necessity” or “coding” at the payer, when the actual failure began earlier in the clinical-to-billing handoff.

Behavioral health has a different structural problem: the service itself may be straightforward, but payment depends on a dense set of rules surrounding who rendered it, how it was rendered, how much care has already been authorized, and what documentation supports continuation of treatment.

Provider enrollment is part of the claim, even when the therapy was clinically appropriate

Behavioral health organizations frequently bill through teams that include different professional types, licenses, supervisors, and group arrangements. Payer recognition of the rendering clinician matters. Medicare, for example, has allowed marriage and family therapists and mental health counselors to enroll and bill independently since January 1, 2024—but they must meet the applicable criteria and complete Medicare enrollment.⁴ A clinically valid psychotherapy session does not overcome an enrollment, reassignment, taxonomy, or payer-network mismatch.

Telehealth is no longer a simple “video visit” flag

Behavioral health remains one of the areas where Medicare telehealth policy is materially different from non-behavioral services. In 2026, mental-health telehealth can continue without the geographic restrictions that apply to many other services, but specific in-person visit requirements now apply in many circumstances for patients receiving mental-health telehealth in the home; RHC and FQHC rules follow a different timeline.⁵ Commercial and Medicaid requirements can differ again. That means place of service, modality, provider eligibility, patient location, and payer-specific policy all belong in the denial analysis—not in a generic “telehealth” bucket.

Medical necessity often operates across an episode, not just a date of service

Psychotherapy payment depends on more than the presence of a diagnosis. CMS coverage guidance emphasizes that psychotherapy must be related to the patient’s condition and medically necessary, with documentation supporting the service furnished; when psychotherapy and E/M are billed together, the services must be separately identifiable.⁶ Other payers may apply utilization review, continued-stay criteria, authorization spans, or visit-management rules. The resulting denial can therefore reflect an episode-management breakdown rather than an individual claim error.

Substance-use records add a privacy workflow that affects authorization and appeals

For organizations subject to 42 CFR Part 2, privacy compliance is not merely a compliance-office issue. The 2024 Part 2 Final Rule required compliance by February 16, 2026 and changed how certain substance-use-disorder records may be used and disclosed while preserving heightened protections.⁷ Part 2 does not itself create a standard claim-denial code. But when records needed for authorization, medical-necessity review, or appeal move through a Part 2 workflow, the revenue cycle must know what can be shared, under what authority, and how to avoid creating an avoidable documentation gap.

Authorization is one of the clearest examples of why specialty context matters. An authorization-related denial is not a root cause. It is a family of failure modes.

If all five are assigned to one queue, the organization can work every denial and learn almost nothing. If they are separated, leadership can see whether the financial problem lives in scheduling, authorization, clinical documentation, provider enrollment, or payer policy.

CMS’s Interoperability and Prior Authorization Final Rule makes 2026 especially relevant for denial intelligence. For impacted payers, CMS requires prior-authorization decisions within 72 hours for expedited requests and seven calendar days for standard requests, and beginning in 2026 requires a specific reason when a non-drug prior-authorization request is denied.⁸

That does not eliminate specialty complexity, and it does not apply identically to every payer or drug authorization. But it improves the raw material available to provider organizations. “Authorization denied” should increasingly be converted into the actual payer-stated reason, then mapped to the internal point of failure.

For an MFM or behavioral health practice, that is the difference between a denial log and a denial intelligence system.

The overall denial rate still belongs on the dashboard. It simply cannot be the whole dashboard. The better question is: Which dollars are failing, why are they failing, where did the failure originate, and is the same root cause repeating?

Then add specialty views. For MFM: global-versus-separately-billable issues, ultrasound and diagnostic medical necessity, diagnosis specificity, co-management/referral patterns, and service-to-authorization matching. For behavioral health: visits or units authorized, continued-treatment review, rendering-provider status, telehealth configuration, treatment-plan/documentation support, and episode-level utilization rules.

When denial performance deteriorates, the reflex is often to add staff, automate edits, change a billing vendor, or push the existing team to “work denials harder.” Each can be appropriate. None should be the first conclusion.

In MFM and behavioral health, a denial inventory is often the downstream evidence of an upstream design problem: payer rules were not translated into scheduling, clinical documentation did not line up with authorization logic, provider enrollment was not synchronized with billing, or the organization’s work queues grouped financially different problems together.

That is why specialty denial management should begin with decomposition, not volume. The objective is not to become faster at appealing the same failure. It is to identify the failure mechanism precisely enough that the next claim never enters the denial queue.